Нейрохолин

Quick links to important sections

Нейрохолин

Treatment option: Cerebrovascular Accident

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Нейрохолин

Property Description
Active ingredient Citicoline (CDP-choline)
Form Oral solution, Tablets, Injectable solution
Pharmacological class Nootropic agent / Psychostimulant
General purpose Supports cognitive function and neuronal membrane integrity
Origin Synthetic compound

Identity and Pharmacological Class of Нейрохолин

Нейрохолин is a pharmaceutical preparation whose sole active ingredient is Citicoline, which is also known by its chemical name cytidine-5′-diphosphocholine or CDP-choline. It is classified under the Anatomical Therapeutic Chemical (ATC) code N06BX06, grouping it with other nootropic agents and psychostimulants. This classification indicates the compound's general use in supporting mental function. Citicoline is a substance with a high safety profile and a role in supporting the recovery of central nervous system function. The active substance is a synthesized form that is biochemically identical to the essential CDP-choline intermediate naturally produced within the body's own metabolic pathways, classifying it as a synthetic compound based on an endogenous intermediate.


General Purpose of Citicoline

The core objective of Citicoline is to provide direct metabolic support for the functional recovery and structural integrity of brain cells. This general benefit stems from its role as a precursor in the biosynthesis of phosphatidylcholine, a major phospholipid component necessary for the maintenance and repair of neuronal membranes. Citicoline functions as a neuroprotective agent that stabilizes cell integrity. The compound contributes to the general preservation of cognitive function—with a typical use being to support memory in elderly patients—and the nervous system's capacity for resilience. The compound contributes to the recovery of brain function following various issues.


Available Pharmaceutical Forms of Нейрохолин

Нейрохолин is manufactured as a single-ingredient product available in several different pharmaceutical presentations. The common dosage form(s) include an oral solution (syrup) and tablets for ingestion, alongside a sterile injectable solution designated for both intravenous and intramuscular delivery. The availability of both oral and parenteral forms is a key distinguishing factor of the formulation, allowing for administration flexibility depending on patient needs. The liquid forms are prepared with an aqueous solution base, ensuring delivery of the Citicoline compound via the designated route of administration.

Regulatory References

  1. neuroprotective agent

What side effects are possible with Нейрохолин?

Possible Side Effects and Safety Information

Official regulatory documentation characterizes the safety profile of Citicoline (the active ingredient in Нейрохолин) as having low toxicity in humans. Adverse effects are generally documented as being infrequent and transient (short-lived).


Official Adverse Reactions by System

Adverse reactions are classified into specific System-Organ Classes (SOCs) in regulatory labeling. The majority of reported effects fall into the following categories:

  • Nervous System Disorders: May include headache, dizziness, insomnia, or excitability.
  • Gastrointestinal Disorders: May involve nausea, diarrhea, abdominal pain, or vomiting.
  • Vascular Disorders: Documented effects include hypotension (low blood pressure), which is typically described as fleeting and discrete.
  • Skin and Subcutaneous Tissue Disorders: Includes reactions such as rash or urticaria (hives).

Most documented effects are classified in the regulatory framework as Uncommon or Rare.


Regulatory Safety Constraints

Certain constraints and restrictions are outlined in official prescribing information:

  • Contraindications: The medicine is explicitly contraindicated in patients with known hypersensitivity to Citicoline or its components, and in those with hypertonia of the parasympathetic nervous system.
  • Intracranial Hemorrhage: Caution is advised, particularly with large doses, in cases of persistent intracranial hemorrhage.
  • Drug Interaction Note: Citicoline must not be administered concomitantly with medicinal products that contain Meclofenoxate.
  • Pregnancy and Lactation: Regulatory caution states that use is only permitted if the potential benefit justifies the potential risk, due to a lack of sufficient safety data in these populations.

Overdose and Emergency Response

Overdose and when to seek help

The information in this section is based strictly on documented findings within official government regulatory prescribing information for Citicoline (Нейрохолин).

Official Regulatory Findings on Overdose

Domain Regulatory Statement
Documented Manifestations Official labeling consistently reports a very low toxicity profile in humans, indicating that the appearance of intoxication is unlikely. No specific overdose cases have been formally reported in regulatory documents.
Dose-Related Notes The substance has been observed to be safe in clinical settings at doses up to 2, g/day, reflecting its broad safety margin.
Antidote No specific antidote for Citicoline overdose is known or documented in the prescribing information.
Procedural Response The required management for an accidental overdose consists solely of symptomatic and supportive therapy.

Mandated Emergency Actions

Official regulatory guidance requires that an individual must seek emergency medical treatment or contact a doctor immediately if an accidental overdose of the oral form is suspected. For the injectable forms, emergency medical treatment will be initiated by a qualified healthcare professional, acknowledging the controlled setting of administration.

Despite the very low intrinsic toxicity profile, this formal requirement to seek immediate medical attention serves to trigger the standardized medical assessment process required by regulatory authorities for any suspected overdose event.

Therapeutic Uses of Нейрохолин

What Нейрохолин Treats: Main Uses and Benefits

Нейрохолин (Citicoline) is used in areas where short-term symptom management is appropriate to address cognitive and neurological symptom patterns. It is applied in clinical settings that involve acute or unstable symptom patterns associated with functional stress. The compound is considered relevant for easing symptom clusters that may become intense or disruptive.

The medicine is commonly used across conditions presenting with acute episodes and chronic cognitive decline, is relevant for managing symptoms of increased neurological or muscular activity following events like Ischemic Stroke or Traumatic Brain Injury (TBI), and provides supportive relief when symptoms interfere with routine activities related to visual function. When symptoms become temporarily overwhelming, it is helpful in situations requiring additional symptomatic assistance to assist with maintaining functional stability. This approach provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations in mental clarity.


Quick Fact: Relief for Cognitive Fatigue The medication may assist with managing symptoms that interfere with daily comfort, such as poor attention, reduced mental clarity, and diminished vigilance during periods of high mental workload.

Eligibility and Restrictions for Use

The eligibility for using Нейрохолин (Citicoline) is determined strictly by the official population-based rules documented in government regulatory sources. These rules define which populations are permitted to use the medicine and which are explicitly excluded.


Eligibility Scope

Classification Population Status
Contraindicated Patients with known hypersensitivity to Citicoline or product components; patients with hypertonia of the parasympathetic nervous system (Vagotonia).
Not Recommended Children and adolescents (pediatric population); pregnant women; breastfeeding women.
Conditional Use Patients with acute or persistent intracranial hemorrhage (bleeding); use is restricted or requires caution.
Allowed Adults with standard labeled indications.

Key Eligibility Rules

Official labeling generally confirms eligibility for adults under standard use. However, use in the pediatric population is not established and therefore not recommended due to insufficient safety and efficacy data. The medicine is also not recommended during pregnancy or breastfeeding for the same reason, advising use only if the benefit is deemed to justify the risk. Furthermore, specific acute conditions, such as a severe intracranial hemorrhage, may restrict eligibility by limiting administration or excluding high doses. No specific restrictions are consistently documented for patients with isolated hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Нейрохолин (Citicoline) outlines specific constraints regarding co-administration with other medicines and substances. This information is based strictly on documentation from authoritative national health authorities, focusing on specific prohibitions and pharmacodynamic effects.


Documented Drug-Drug Interactions

Interaction Type Interacting Substance Official Regulatory Statement
Formal Contraindication Meclofenoxate (Centrophenoxine) Co-administration is explicitly prohibited; the medicine must not be administered with products containing Meclofenoxate.
Pharmacodynamic Effect L-dopa (Levodopa) Citicoline potentiates the effects of L-dopa, resulting in an increase in the pharmacological action of the anti-parkinsonian agent.

Substance and General Restrictions

While there are no broad statements concerning pharmacokinetic interactions via CYP enzymes or drug transporters, the official prescribing information includes a mandatory substance restriction. Individuals using this preparation must avoid the consumption of alcoholic beverages.

Regulatory documents do not specify any mandatory time separation requirements for doses of interacting medicines, nor do they contain explicit notes regarding heightened interaction severity in specific patient populations, such as those with hepatic impairment.

Mechanism of Action

Нейрохолин is a novel cholinergic modulator that operates primarily by targeting the mathbfalpha 7 nicotinic acetylcholine receptor (nAChR) subtype. It acts with high affinity as a partial agonist on these receptors, which are densely expressed within the central nervous system. This initial binding event facilitates the influx of Ca^2+ ions into the presynaptic terminal.

This receptor interaction triggers an immediate intracellular signaling cascade. Specifically, the activation of the alpha 7 nAChR leads to the downstream phosphorylation of extracellular signal-regulated kinases ( ERK1/2) and the concurrent activation of the PI3K/Akt pathway. Нейрохолин further modulates key second messenger systems, resulting in the stabilization of the cyclic AMP ( cAMP) response element-binding protein (CREB).

The cumulative result of these intracellular processes is the modulation of neurotransmitter release kinetics, primarily affecting acetylcholine and glutamate in several brain regions. This modification of the signaling equilibrium subsequently alters synaptic plasticity and affects the consistency of signal transmission between neural circuits.

Dosage and Administration Information

How to Use Нейрохолин

Нейрохолин (Citicoline) is administered using a structured protocol that utilizes multiple pharmaceutical forms and routes of delivery. The medicine is available for Oral intake (as tablets or solution) and for Parenteral administration, specifically Intramuscular (IM) and Intravenous (IV) injection.


Standard Dosing and Schedule

For adults, the typical total daily dose ranges from 500 mg to 2000 mg (2 g). Dosing is generally prescribed for once or twice daily administration. The oral forms may be taken with or between meals. The duration of the treatment course is determined based on the severity of the neurological issue, often involving an initial phase of parenteral use followed by a transition to oral administration for continuation.


Procedural and Population Rules

Specific administration rules govern its use. Intravenous injection must be administered slowly, typically over 3 to 5 minutes. A key procedural restriction dictates that the solution must not be administered in conjunction with medications containing meclofenoxate. For older adults, no dose adjustment is required.

Recent Clinical Evidence

Evidence for use in Acute Ischemic Stroke and Recovery

Research on Нейрохолин in this area has primarily involved randomized controlled trials (RCTs) and meta-analyses exploring how functional recovery and the severity of neurological symptoms change over defined time intervals following an acute ischemic stroke. Outcomes reflecting daily functioning or activity level were measured using tools like the Modified Rankin Scale and the Barthel Index.

Findings from large research scenarios have been mixed. While some studies report how symptoms evolved over the short term, overall measured outcomes between the study group and the control group were often similar in several major recent RCTs. Research highlights changes measured in specific subgroups of patients, where some patterns of differences in measured outcomes were observed in the studied population compared to the control group.

The certainty remains low regarding the measured outcomes across the entire population of stroke patients studied. Key limitations include the reliance on subgroup findings and post-hoc analyses. The results apply only to the populations studied and do not make individual predictions.


Evidence for use in General Cognitive Impairment and Decline

Нейрохолин was studied for its use in individuals with age-related decline in memory and thinking skills. Research here includes systematic reviews of RCTs that examined various cognitive domains, including attention, executive functions, and memory, using standardized neurocognitive testing.

Findings describe patterns observed in some study populations. Changes in memory scores were reported in some evidence from subjects over 50 years old. However, evidence quality varies across studies, and others reported similar findings between the study group and the control group on major cognitive scales. Uncertainty remains low due to the variable quality of the available evidence. Follow-up durations were limited in many trials, meaning long-term measured outcomes are not fully established regarding the sustained stability of cognitive status after the observation period ended.


Key Limitations and Remaining Uncertainties

Research provides context but not individual predictions. The overall evidence landscape for Нейрохолин still contains several uncertainties that limit the ability to draw definitive conclusions:

  • Evidence Quality: Evidence quality varies across studies, with many older trials having a noted risk of bias in their design.
  • Inconsistent Findings: The findings were mixed in some large, high-quality randomized controlled trials.
  • Data Gaps: Comparative evidence is lacking against standard established therapies for many potential indications.

These limitations mean that while studies contribute to the broader evidence landscape, a clearer understanding of the data requires more contemporary, large-scale research.

Key Studies & References

  1. Role of Citicoline in Cognitive Impairment and Stroke: Clinical Evidence and Limitations (Systematic Review)

Frequently Asked Questions (FAQ)

Common questions about Нейрохолин (FAQ)


Q: Is Нейрохолин the same thing as choline or other choline supplements?

Нейрохолин is the brand name for Citicoline, which is also known as CDP-choline. This compound is a specific intermediate that the body uses as a precursor to create phosphatidylcholine, a crucial component for cell membrane repair. Therefore, the official substance is not the same as simpler nutritional choline salts or basic choline supplements.


Q: What conditions is Нейрохолин typically used to treat in official medical practice?

Official product information describes Нейрохолин's use in providing metabolic support for brain cells and supporting functional recovery. In clinical practice, its use has been studied and documented in contexts such as recovery from acute ischemic stroke. It is also explored for subjects experiencing age-related decline in memory and thinking skills.


Q: Can Нейрохолин be taken long-term, or should I cycle it?

The official duration of treatment is determined by the severity of the specific neurological issue. Some regulatory documents suggest that the medicine is generally not intended for use over long periods. Official guidelines for continued use beyond a certain period, such as three months, emphasize the need for professional medical review.


Q: Are there any specific foods or drinks that should be avoided when taking Нейрохолин?

Official regulatory documents include a mandatory substance restriction stating that patients must avoid the consumption of alcoholic beverages while using this preparation. No other specific restrictions concerning food or non-alcoholic drinks are typically mentioned in the core regulatory documentation.


Q: Does Нейрохолин help to increase mental energy or focus?

Нейрохолин is chemically classified as a psychostimulant and is intended to support overall cognitive function. Scientific literature contains studies that have investigated the medicine's potential to positively influence specific cognitive aspects such as focus and attention.


Q: Does Нейрохолин have any known effects on mood or anxiety?

The safety profile derived from official documentation includes excitability as a possible nervous system disorder. While the effects on mood or anxiety are not major documented adverse effects, some studies have examined the potential for adverse psychiatric outcomes, a hypothesis which the evidence does not clearly support.


Q: Does taking Нейрохолин improve overall quality of life according to research?

Research on this medicine has included measuring outcomes related to daily functioning and activity level, often using validated tools like the Barthel Index. However, official evidence summaries generally do not make explicit claims regarding a broad improvement in a person's overall quality of life.


Q: What is the maximum duration of treatment with Нейрохолин mentioned in clinical data?

The length of a treatment course for Нейрохолин is typically determined by the complexity and severity of the patient's neurological condition. According to certain regulatory sources, treatment continuing beyond three months is subject to professional medical review.


Q: Is there any official information on using Нейрохолин for recovery after a concussion?

The general purpose of the medicine is to provide metabolic support for the functional recovery of brain cells after various issues. Official medical literature and clinical registers show that the active ingredient, Citicoline, has been investigated in clinical settings involving head trauma.


Q: How long does it usually take to feel the effects of Нейрохолин?

Pharmacokinetic studies indicate that after taking an oral dose, the constituent parts of the medicine begin to rise in the blood within six to eight hours. The maximum plasma concentration of the compound itself occurs in a dual-peak pattern, usually observed around one hour and then again 24 hours after ingestion.


Q: Can Нейрохолин be taken at the same time as my daily vitamins?

Official regulatory interaction checks only list specific drug prohibitions, such as Meclofenoxate, and a noted potentiation effect with L-dopa. There are generally no mandatory warnings or prohibitions issued in regulatory documents regarding the use of common daily vitamin or mineral supplements.


Q: Is there a risk of developing a dependence on Нейрохолин?

Based on safety reviews, the active ingredient in Нейрохолин exhibits a very low toxicity profile in humans. Official regulatory documents detailing the safety information do not contain any mention or identification of a risk related to developing physical dependence on the medicine.


Q: Is it safe to use Нейрохолин with blood pressure medication?

The official safety profile notes that Нейрохолин can cause transient (fleeting) hypotension (lowering of blood pressure). Official labeling advises caution when the medicine is administered alongside other prescribed medications that are specifically used to lower blood pressure, due to the potential for further lowering blood pressure.


Q: Does Нейрохолин interact with common pain relievers or supplements?

The formal drug interaction documentation only lists the absolute prohibition of co-administration with Meclofenoxate and a potentiating effect with L-dopa. There are no specific warnings or prohibitions listed in official regulatory documents regarding the use of common non-prescription pain relievers.


Q: Can people with a history of heart issues safely use Нейрохолин?

Official safety information indicates that the medicine can cause transient hypotension, meaning a temporary drop in blood pressure. The product information includes specific caution regarding use in patients who may already have low blood pressure. No specific contraindication related to a general history of heart issues is noted in regulatory documents.


Q: What happens if a dose of Нейрохолин is accidentally missed?

This question requires individualized advice regarding dosing schedules and specific patient needs, which is not provided in this regulatory FAQ. Always consult your healthcare provider or refer to the specific patient information leaflet provided by your pharmacist for instructions on how to handle missed doses.


Q: Can Нейрохолин affect appetite or body weight?

While official adverse effect listings include common gastrointestinal issues like nausea, they do not frequently document weight or appetite changes. Some research has examined these outcomes, reporting mild declines in appetite ratings at higher doses, but generally no significant change in body weight over the study period.


Q: Is Нейрохолин absorbed well when taken orally?

Pharmacokinetic studies show that Нейрохолин (Citicoline) is a water-soluble compound. Following oral administration, the medicine is described as being rapidly absorbed, with studies reporting its oral bioavailability as high as greater than 90%.


Q: Is Нейрохолин available over the counter, or is it prescription-only?

The availability of Нейрохолин is known to vary based on location and the specific pharmaceutical form. While injectable forms are typically restricted to prescription use, the oral form of the active ingredient is available as an over-the-counter (OTC) product in certain regions.

How should Нейрохолин be stored and disposed of?

The official storage and disposal instructions for Нейрохолин (Citicoline) are defined by government regulatory agencies to ensure product quality and safety.

Official Storage and Handling

Condition Regulatory Requirement
Temperature Store below 25 C or 30 C, depending on the specific product label. Do not refrigerate or freeze the medication.
Protection Keep the product in the original package to protect it from light and moisture. Keep liquid containers tightly closed.
Stability Do not use after the expiry date. The oral solution has a limited shelf-life, typically requiring disposal four weeks after first opening.
Child Safety The medicine must be kept out of the sight and reach of children.

Disposal Requirements

Any unused or expired Нейрохолин must be disposed of in accordance with local regulations for medicinal products. It is prohibited to dispose of the medicine via wastewater (flushing down the toilet or sink) or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Нейрохолин found in:

A-Z Index: